Cristiane Bergerot and Maryam Lustberg highlight a trial where duloxetine at 30 or 60 mg did not reduce oxaliplatin induced peripheral neuropathy versus placebo, underscoring prevention gaps and placebo effects in symptom trials.
We can treat painful neuropathy, but can we prevent it?
This trial shows duloxetine (30 or 60 mg) did not reduce OIPN vs placebo.
the strong placebo effect in symptom management studies
This finding is one of many signals tracked across Healthcare. The live feed updates every few hours with new expert voices, debates, and emerging ideas.
← Back to Healthcare